Article: Research and Markets: Eli Lilly and Company Medical Equipment Company Share Analysis Inspects The Company's Strategy in Terms of Its Value Chain Positioning.(Company overview)

Article: Eli Lilly/ICOS's Cialis Will Gain Market ...
PR Newswire;  September 27, 2005 ;     700+ words ... ... pharmaceutical and health care issues, finds that therapies such as Eli Lilly/ICOS's Cialis (tadalafil) have improved side-effect profiles over existing drugs and will gain market share owing to their increased use in combination therapy to treat ...

Article: Amylin Pharmaceuticals Inc.(Medical Stock Spotlight)(Eli ...
MondayMorning;  December 15, 2008 ;     598 words ... ... is developing the once-weekly version of the medicine that is now taken twice a day with Eli Lilly & Co. and Alkermes Inc. (Nasdaq). Eli Lilly (NYSE) closed the week up $1.47, or 4%, at $36.41 while Alkermes (Nasdaq) jumped ...

Article: Despite Negative Impact of WHI and HERS II Studies, the Hormone ...
PR Newswire;  April 8, 2003 ;     700+ words ... ... Replacement Therapy, one such drug that will take advantage of patients' and physicians' concerns with traditional HRT products is Eli Lilly's Evista. Evista is currently the only selective estrogen receptor modulator (SERM) approved for the prevention and treatment ...

Article: Eli Lilly and Company: Strattera Prescriptions ...
Business Wire;  October 16, 2003 ;     700+ words ... ... Hyperactivity Disorder, Eli Lilly and Company (NYSE:LLY ... September 30, Strattera's market share rose to 16.3 percent from ... R) had 24.0 percent market share in September and Adderall XR(R) had 22.4 percent market share. Through September 30 ...

Article: Eli Lilly's Ruboxistaurin, The First ...
PR Newswire;  December 16, 2002 ;     700+ words ... ... on pharmaceutical and health care issues, forecasts that Eli Lilly's ruboxistaurin, the first disease-modifying agent for ... market. Ruboxistaurin will attain nearly two-thirds of market share by 2011, according to a new Pharmacor report entitled Diabetic ...

Article: Biotechnology company Alkermes Inc (Cambridge MA) forecast a ...
MondayMorning;  June 23, 2008 ;     700+ words ... ... Biotechnology company Alkermes Inc (Cambridge MA) forecast a surprise profit for fiscal 2009, saying part of a payment from Eli Lilly & Co (Indianapolis IN) related to its inhaled insulin program would be recognized as revenue in the first quarter ...

Article: Eli Lilly And Company Medical Equipment Company ...
M2 Presswire;  September 15, 2008 ;     700+ words ... ... of Generic Drugs 9 Competitors 10 Eli Lilly and Company Medical Equipment Market Share Analysis 10.1 Eli Lilly and Company, Global, Market Share (2006) 10.2 Eli Lilly and Company, APAC, Market Share (2006) 10.3 Eli Lilly and ...